July 8, 2022 Patent Open Access

Alkoclar, Erdal Can; Yesil, Metehan

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.82163/sciencerepository.24</identifier>
  <creators>
    <creator>
      <creatorName>Alkoclar, Erdal Can</creatorName>
      <givenName>Erdal Can</givenName>
      <familyName>Alkoclar</familyName>
      <affiliation>Mas Pharmaceuticals</affiliation>
    </creator>
    <creator>
      <creatorName>Yesil, Metehan</creatorName>
      <givenName>Metehan</givenName>
      <familyName>Yesil</familyName>
    </creator>
  </creators>
  <titles>
    <title>An Antiviral Formulation with RNA Dependent RNA Polymerase &amp; DNA Gyrase Suppressive Properties for the Treatment of Emerging Covid-19 Subvariants</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2022</publicationYear>
  <subjects>
    <subject>Omicron covid-19</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2022-07-08</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="Text">Patent</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://sciencerepository.dk/record/24</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.82163/sciencerepository.23</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://sciencerepository.dk/communities/science_repository_dk</relatedIdentifier>
  </relatedIdentifiers>
  <version>1.0</version>
  <rightsList>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;A bioceutical formulation consisting of RNA Polymerase inhibiting and immunomodulatory features- exhibiting Glucopyranoside Analouges for the Adjunctive Treatment of Emerging Covid-19 Subvariants.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Inventors: Erdal Can Alkoclar &amp;amp; Metehan Yesil&lt;/p&gt;</description>
  </descriptions>
</resource>